Aluminum hydroxide + cpg
Aluminum hydroxide + cpg has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Nov 17, 2021: “An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice”.
1 paper studies it2 findingsUpdated
See all 1 papers on aluminum hydroxide + cpg
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Baylor University and others
- 2 of 2 findings with company ties
- Animals1
What did studies of aluminum hydroxide + cpg find?
2Studies of aluminum hydroxide + cpg measured 2 outcomes: COVID-19 and anti-RBD neutralizing antibody titers.
COVID-19
downin mice1
1 study
COVID-19
downin mice1
Aluminum hydroxide + cpg protects against COVID-19 in mice (SARS-CoV-2 challenge).
“protected aged mice from the SARS-CoV-2 challenge”
AnimalsSARS-CoV-2 challenge
Science translational medicine
Anti-RBD neutralizing antibody titers
upin mice1
1 study
Anti-RBD neutralizing antibody titers
upin mice1
Aluminum hydroxide + cpg increases anti-RBD neutralizing antibody titers in mice (SARS-CoV-2 challenge) (80-fold increase).
“AH and CpG adjuvant formulation (AH:CpG) produced an 80-fold increase in anti-RBD neutralizing antibody titers in both age groups relative to AH alone”
AnimalsSARS-CoV-2 challenge
Science translational medicine